General Information of the m6A Target Gene (ID: M6ATAR00378)
Target Name Retinoic acid receptor alpha (RARA)
Synonyms
RAR-alpha; Nuclear receptor subfamily 1 group B member 1; NR1B1
    Click to Show/Hide
Gene Name RARA
Chromosomal Location 17q21.2
Family nuclear hormone receptor family; NR1 subfamily
Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone deacetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. Formation of a complex with histone deacetylases might lead to inhibition of RARE DNA element binding and to transcriptional repression. Transcriptional activation and RARE DNA element binding might be supported by the transcription factor KLF2. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis (By similarity). Has a role in the survival of early spermatocytes at the beginning prophase of meiosis (By similarity). In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes (By similarity). In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Together with RXRA, positively regulates microRNA-10a expression, thereby inhibiting the GATA6/VCAM1 signaling response to pulsatile shear stress in vascular endothelial cells
    Click to Show/Hide
Gene ID 5914
Uniprot ID
RARA_HUMAN
HGNC ID
HGNC:9864
Ensembl Gene ID
ENSG00000131759
KEGG ID
hsa:5914
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
RARA can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and Retinoic acid receptor alpha (RARA) by reducing m6A levels in these mRNA transcripts.
Target Regulation Down regulation
Responsed Disease Acute myeloid leukaemia ICD-11: 2A60
Responsed Drug Tretinoin Approved
Cell Process RNA stability
RNA degradation (hsa03018)
In-vitro Model K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
KOCL-48 Childhood acute monocytic leukemia Homo sapiens CVCL_6867
Mono-Mac-6 Adult acute monocytic leukemia Homo sapiens CVCL_1426
Acute myeloid leukaemia [ICD-11: 2A60]
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and Retinoic acid receptor alpha (RARA) by reducing m6A levels in these mRNA transcripts.
Responsed Disease Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
Target Regulation Down regulation
Responsed Drug Tretinoin Approved
Cell Process RNA stability
RNA degradation (hsa03018)
In-vitro Model K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
KOCL-48 Childhood acute monocytic leukemia Homo sapiens CVCL_6867
Mono-Mac-6 Adult acute monocytic leukemia Homo sapiens CVCL_1426
Tretinoin [Approved]
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and Retinoic acid receptor alpha (RARA) by reducing m6A levels in these mRNA transcripts.
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
Target Regulation Down regulation
Responsed Disease Acute myeloid leukaemia ICD-11: 2A60
Cell Process RNA stability
RNA degradation (hsa03018)
In-vitro Model K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
KOCL-48 Childhood acute monocytic leukemia Homo sapiens CVCL_6867
Mono-Mac-6 Adult acute monocytic leukemia Homo sapiens CVCL_1426
References
Ref 1 FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer Cell. 2017 Jan 9;31(1):127-141. doi: 10.1016/j.ccell.2016.11.017. Epub 2016 Dec 22.